BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.6701
-0.0293 (-4.19%)
Nov 3, 2025, 10:18 AM EST - Market open
BioAtla Employees
BioAtla had 61 employees as of December 31, 2024. The number of employees decreased by 4 or -6.15% compared to the previous year.
Employees
61
Change (1Y)
-4
Growth (1Y)
-6.15%
Revenue / Employee
$180,328
Profits / Employee
-$975,656
Market Cap
39.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | -4 | -6.15% |
| Dec 31, 2023 | 65 | -1 | -1.52% |
| Dec 31, 2022 | 66 | 10 | 17.86% |
| Dec 31, 2021 | 56 | 20 | 55.56% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAB News
- 11 days ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire
- 14 days ago - BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 - GlobeNewsWire
- 4 weeks ago - BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewsWire
- 2 months ago - BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA - GlobeNewsWire
- 3 months ago - BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 3 months ago - BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 - GlobeNewsWire
- 3 months ago - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - GlobeNewsWire